

Supprelin® LA

(histrelin acetate subcutaneous implant)

When requesting Supprelin® LA (histrelin acetate subcutaneous implant), the individual requiring treatment must be diagnosed with the following FDA-approved indication and meet the specific coverage guidelines.

FDA-approved indication(s)

Supprelin® LA (histrelin acetate subcutaneous implant) is indicated for the treatment of children with central precocious puberty.

Coverage Guidelines

The individual meets the following criteria for approval:

- 1) Has the diagnosis of central precocious puberty

Approval duration (initial and renewal): 12 months

Recommended dosing

50 mg implant inserted subcutaneously in the upper arm every 12 months

References

1. Supprelin® LA [prescribing information]. Malvern, PA; Endo Pharmaceuticals Solutions Inc., May 2017.
2. Harrington J, Palmert MR. Treatment of precocious puberty. Available at: uptodate.com. Updated September 26, 2017. Accessed on September 7, 2018.
3. Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. *Pediatrics*. 2009 Apr; 123(4):e752-62.